Investment
Features
FeesSafety
Academy
More
Pluang+

Compare McKesson Corporation (MCK) vs Tesla, Inc. (TSLA) Price & Performance

McKesson CorporationTrade
Tesla, Inc.Trade

Price performance (Past 24H)

Key statistics

McKesson Corporation vs Tesla, Inc. — how do they compare? McKesson Corporation trades at $930 (market cap $108.46B), while Tesla, Inc. trades at $379 (market cap $1.48T). The key difference: Tesla, Inc. is far larger — about 13.6× McKesson Corporation's market cap, and McKesson Corporation pays a 0.4% dividend while Tesla, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold McKesson Corporation for 74 Days and Tesla, Inc. for 88 Days on average.

MCKTSLA
Market Cap
$108.46B$1.48T
Volume
712,60728,215,427
Sector
HealthConsumer Cyclical
52-Week High
$995.69$489.88
52-Week Low
$725.17$298.16
Typical Hold Time
74 Days88 Days
Enterprise Value
$115.00B$1.45T
Dividend Yield
0.4%—

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

McKesson Corporation

McKesson Corporation (MCK) trades at $910.33, down 1.23% today, but maintains strong analyst support with 80.65% buy ratings and a $956.43 consensus price target. The stock shows bullish technical momentum with recent earnings beats and a major distribution agreement extension with CVS Health through 2032. Revenue growth has accelerated from $264B in 2022 to $359B in 2025, though net margins remain thin at 1.12%.

MCK presents a compelling growth story with consistent earnings outperformance and strategic partnerships driving long-term visibility. However, investors face risks from margin compression, drug pricing pressures, and high leverage with negative shareholder equity. The current valuation at 24.42x P/E appears reasonable given the company's market leadership and oncology growth prospects.

Tesla, Inc.

Tesla (TSLA) trades at $377.61, down 0.81% amid mixed signals. Technical analysis shows a bullish trend with key support at $375, while fundamentals reveal high valuation multiples (P/E 349.82) despite recent earnings beats. The company faces margin compression with net income declining to $3.79B in 2025. Recent news highlights regulatory approval for driver-assistance software in Europe (Reuters, 2026-04-10) and a potential cheaper EV model launch.

Tesla's investment case balances innovation leadership against valuation concerns. Upside potential exists from autonomous driving advances and energy/robotics growth, but risks include intense EV competition and execution challenges. Analysts maintain a cautious stance with 41% buy ratings and a $441.36 consensus target, suggesting modest upside from current levels.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

MCK
40% Buy60% Sell
Avg holding period · 74 Days
TSLA
16% Buy84% Sell
Avg holding period · 88 Days

Top news

Latest headlines on both assets

About McKesson Corporation

McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.

Read more on MCK →

About Tesla, Inc.

Tesla Inc. designs, manufactures, and sells high-performance electric vehicles and electric vehicle powertrain components. The Company owns its sales and service network and sells electric power train components to other automobile manufacturers. Tesla serves customers worldwide.

Read more on TSLA →